References
- Chan ATC, Lo YMD, Zee B, et al (2002). Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst, 94, 1614-9. https://doi.org/10.1093/jnci/94.21.1614
- Chang KP, Hsu CL, Chang YL, et al (2008). Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma. Oral Oncol, 44, 784-92. https://doi.org/10.1016/j.oraloncology.2007.10.003
- Chan KCA, Lo YMD (2002). Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma. Cancer Biol, 12, 489-96. https://doi.org/10.1016/S1044579X02000913
- Chan KH, Gu YL, Ng F, et al (2003). EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma. Int J Cancer, 105, 706-9. https://doi.org/10.1002/ijc.11130
- Fan H, Nicholls J, Chua D, et al (2004). Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus. Int J Cancer, 112, 103641.
- Feng HY, Huang YJ, Zhou XY, et al (2009). Diagnosis of NPC with Plasma EBV DNA. Journal of Tropical Medicine, 9, 913-5.
- Kong P (2010). The clinical value of the quantitative determination of EBV-DNA in blood serum and PBMC patients with nasopharyngeal carcinoma. J Shandong Med College, 32, 321-4.
- Leung SF, Tam JS, Chan AT, et al (2004). Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. Clin Chem, 50, 339-45. https://doi.org/10.1373/clinchem.2003.022426
- Liao LY, Kong M, Liu CJ (2010). Comparison of detection of white blood cell's EBV DNA and plasma's VCA-IgA in nasopharyngeal carcinoma patients. Med Innov China, 7, 145-6.
- Lin JC, Chen KY, Wang WY, et al (2001). Detection of Epstein-Barr virus DNA in the peripheral-blood cells of patients with nasopharyngeal carcinoma: relationship to distant metastasis and survival. J Clin Oncol, 19, 2607-15.
- Lo YMD, Chan LY, Chan AT, et al (1999). Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res, 59, 5452-5.
- Lo YMD, Chan LYS, Lo KW, et al (1999). Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res, 59, 1188-99.
- Lo YMD, Leung S, Chan LY, et al (2000). Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res, 60, 2351-5.
- Luo YL, Ou GP, Chi PD, et al (2009). Combined determination of Epstein-barr virus related antibodies and antigens for diagnosis of nasopharyngeal carcinoma. Chinese Journal of China, 28, 96-9.
- Mai S, Zong Y, Zhang M, et al (2002). Detection of Epstein-Barr virus DNA in plasma/serum: a useful serological indicator for diagnosis of nasopharyngeal carcinoma. Chin Med J, 115, 1895-7.
- Mutirangura A, Pornthanakasem W, Theamboonlers A, et al (1998). Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. Clin Cancer Res, 4, 665-9.
- Ng WT, Choi CW, Lee MC, et al (2010). Outcomes of nasopharyngeal carcinoma screening for high risk family members in Hong Kong. Fam Cancer, 9, 221-8. https://doi.org/10.1007/s10689-009-9296-y
- Shao JY, Zhang Y, Li YH, et a1 (2004). Comparison of Epstein- Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma. Anticancer Res, 24, 4059-66.
- Sharma TD, Singh TT, Laishram RS, et al (2011).Nasopharyngeal carcinoma--a clinico-pathological study in a regional cancer centre of northeastern India. Asian Pac J Cancer Prev, 12, 1583-7.
- Shotelersuk K, Khorprasert C, Sakdikul S, et al (2000). Epstein-Barr virus DNA in serum/plasma as a tumor marker for nasopharyngeal cancer. Clin Cancer Res, 6, 1046-51.
- Sun JG, Wang HX, Xiao FG, et al (2010). Clinical application of plasma ell free EBV DNA, serum CYFR A21-1 and VCAIgA in patients with nasopharyngeal carcinoma. Modern Oncology, 18, 1930-2.
- Sun JG, Zheng AP (2008). Clinical significance of plasma EBV DNA and VCA-IgA for nasopharyngeal carcinoma. Modern Oncol, 16, 2086-7.
- Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
- Tan YJ, Su XK, Cui JH (2010). Comparison of detection of serum VCA-lgA, EA-IgA and EBV-DNA in nasopharyngeal carcinoma patient. Chongqing Med J, 39, 703-6.
- Tsang RK, Vlantis AC, Ho RW, et al (2004). Sensitivity and specificity of Epstein-Barr virus IgA titer in the diagnosis of nasopharyngeal carcinoma: a three-year institutional review. Head Neck, 26, 598-602. https://doi.org/10.1002/hed.20022
- Wei K, Xu Y, Liu J, Zhang W, Liang Z (2010). No incidence trends and no change in pathological proportions of nasopharyngeal carcinoma in Zhongshan in 1970-2007. Asian Pac J Cancer Prev, 11, 1595-9.
- Wei WI, Sham JS, Zong YS, et al (1991). The efficacy of fiberoptic endoscopic examination and biopsy in the detection of early nasopharyngeal carcinoma. Cancer, 67, 3127-30. https://doi.org/10.1002/1097-0142(19910615)67:12<3127::AID-CNCR2820671231>3.0.CO;2-R
- Yang X, Goldstein AM, Chen CJ (2006). Distribution of Epstein-Barr viral load in serum of individuals from nasopharyngeal carcinoma high-risk families in Taiwan. Int J Cancer, 118, 780-4. https://doi.org/10.1002/ijc.21396
- Zeng Y, Zhang LG, Li HY, et al (1982). Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. Int J Cancer, 29, 139-41. https://doi.org/10.1002/ijc.2910290204
- Zeng Y, Zhang LG, Wu YC, et al (1985). Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer, 36, 545-7. https://doi.org/10.1002/ijc.2910360505
- Zeng Y, Zhong JM, Li LY, et al (1983). Follow-up studies on Epstein-Barr virus IgA/ VCA antibody-positive persons in Zangwu County, China. Intervirology, 20, 1990-4.
- Zhang LW, Luo BQ, Dou XQ, et al (2012). Quantitative analysis of Epstein-Barr virus DNA in saliva, blood serum and peripheral blood cells in patients with nasopharyngeal carcinoma. Chin J Otorhinolaryngol Skull Base Surg, 18, 24-7.
- Zhang Y, Gao HY, Feng HX, et al (2004). Quantitative analysis of Epstein-Barr virus DNA in plasma and peripheral blood cells in patients with nasopharyngeal Carcinoma. Natl Med J Chin, 84, 982-6.
- Zhu HF, He X (2012). Significance of detecting plasma EBV DNA and VCA-IgA in patients with nasopharyngeal carcinoma. J Chin Oncol, 18, 111-3.
- Zong YS, Sham JS, Ng MH, et al (1992). Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer, 69, 3-7. https://doi.org/10.1002/1097-0142(19920101)69:1<3::AID-CNCR2820690104>3.0.CO;2-7
Cited by
- Expression of the Pokemon Proto-oncogene in Nasopharyngeal Carcinoma Cell Lines and Tissues vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6315
- Prognostic implication of neuropilin-1 upregulation in human nasopharyngeal carcinoma vol.8, pp.1, 2013, https://doi.org/10.1186/1746-1596-8-155
- Microtubule depolymerization activates the Epstein-Barr virus lytic cycle through protein kinase C pathways in nasopharyngeal carcinoma cells vol.94, pp.Pt_12, 2013, https://doi.org/10.1099/vir.0.058040-0
- Biomarker discovery of nasopharyngeal carcinoma by proteomics vol.11, pp.2, 2014, https://doi.org/10.1586/14789450.2014.897613
- ABO Blood Group, Epstein-Barr virus Infection and Prognosis of Patients with Non-metastatic Nasopharyngeal Carcinoma vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7459
- Diagnostic Significance of Combined Detection of Epstein-Barr Virus Antibodies, VCA/IgA, EA/IgA, Rta/IgG and EBNA1/IgA for Nasopharyngeal Carcinoma vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.2001
- C5a promotes the proliferation of human nasopharyngeal carcinoma cells through PCAF-mediated STAT3 acetylation vol.32, pp.5, 2014, https://doi.org/10.3892/or.2014.3420
- Sinonasal Tract Inflammation as a Precursor to Nasopharyngeal Carcinoma vol.154, pp.5, 2016, https://doi.org/10.1177/0194599816629436
- The Role of Epstein-Barr Virus DNA Load and Serology as Screening Tools for Nasopharyngeal Carcinoma vol.155, pp.2, 2016, https://doi.org/10.1177/0194599816641038
- Differential prevalence and correlates of whole blood Epstein–Barr virus DNA between HIV-positive and HIV-negative men who have sex with men in Shanghai, China vol.145, pp.11, 2017, https://doi.org/10.1017/S0950268817001054
- Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population vol.18, pp.1, 2018, https://doi.org/10.1186/s12885-017-3718-2
- Evaluation of circulating EBV microRNA BART2-5p in facilitating early detection and screening of nasopharyngeal carcinoma vol.143, pp.12, 2018, https://doi.org/10.1002/ijc.31642
- Assessment of the radiotherapy effect for nasopharyngeal cancer using plasma surface-enhanced Raman spectroscopy technology vol.9, pp.7, 2018, https://doi.org/10.1364/BOE.9.003413
- Gemcitabine and cisplatin regimen facilitates prognosis of advanced nasopharyngeal carcinoma vol.7, pp.7, 2018, https://doi.org/10.1002/cam4.1575
- Apigenin inhibits C5a-induced proliferation of human nasopharyngeal carcinoma cells through down-regulation of C5aR vol.38, pp.3, 2018, https://doi.org/10.1042/BSR20180456
- Roles of β-catenin, TCF-4, and survivin in nasopharyngeal carcinoma: correlation with clinicopathological features and prognostic significance vol.19, pp.1, 2019, https://doi.org/10.1186/s12935-019-0764-7